For example, the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway was a potential therapeutic target in the tumor, the activation of which cleared the ROS in MDSCs and decreased the risk of tumor metastasis [147, 148]. Here, NFE2L2 is linked to neoplasm.